drugset
drugset / Trial / NCT04384367

Efficacy and Safety of Rizatriptan-Naproxen (10/550 Mg) in the Acute Treatment of Migraine

NCT04384367 ↗

Phase 3 Completed 2068 enrolled Eurofarma Laboratorios S.A.
RandomizedParallel-groupTriple-blindTreatment

Summary

A phase III study, multicenter, double-blind, double-dummy, randomized, single-dose, placebo-controlled study to evaluate the efficacy and safety of Rizatriptan-Naproxen (10/550 mg) in the acute treatment of migraine. ⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).

Timeline

Start
2022-12-30
Primary completion
2024-10-30
Completion
2024-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Naproxen Small molecule 550 mg Oral
Subject rizatriptan Unknown 10 mg Oral

Indications

migraine disorder